Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2001-2-9
pubmed:abstractText
To improve cytotoxicity of 10-deoxy-10-C-morpholinoethyl docetaxel analogues against various tumor cell lines including resistant cells expressing P-glycoprotein (P-gp), we modified the 7-hydroxyl group to hydrophobic groups (methoxy, deoxy, 6,7-olefin, alpha-F, 7-beta-8-beta-methano, fluoromethoxy). Among these analogues, the 7-methoxy analogue showed the strongest cytotoxicity. This analogue showed potent activity against B16 melanoma BL6 in vivo by oral administration.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0960-894X
pubmed:author
pubmed:issnType
Print
pubmed:day
12
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
407-10
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:11212122-Administration, Oral, pubmed-meshheading:11212122-Animals, pubmed-meshheading:11212122-Antineoplastic Agents, Phytogenic, pubmed-meshheading:11212122-Cell Division, pubmed-meshheading:11212122-Combinatorial Chemistry Techniques, pubmed-meshheading:11212122-Drug Screening Assays, Antitumor, pubmed-meshheading:11212122-Humans, pubmed-meshheading:11212122-Inhibitory Concentration 50, pubmed-meshheading:11212122-Lung Neoplasms, pubmed-meshheading:11212122-Melanoma, Experimental, pubmed-meshheading:11212122-Mice, pubmed-meshheading:11212122-Mice, Inbred C57BL, pubmed-meshheading:11212122-Morpholines, pubmed-meshheading:11212122-Paclitaxel, pubmed-meshheading:11212122-Solubility, pubmed-meshheading:11212122-Structure-Activity Relationship, pubmed-meshheading:11212122-Survival Rate, pubmed-meshheading:11212122-Taxoids, pubmed-meshheading:11212122-Tumor Cells, Cultured
pubmed:year
2001
pubmed:articleTitle
Orally active docetaxel analogue: synthesis of 10-deoxy-10-C-morpholinoethyl docetaxel analogues.
pubmed:affiliation
New Product Research Laboratories IV, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.
pubmed:publicationType
Journal Article